Clinic representatives and aesthetic practitioners gathered at Home House in London for the SculpSure Meet the Expert event on June 15.
The US Food and Drug Administration (FDA) has approved Allergan to market JUVÉDERM VOLBELLA XC for lip augmentation and to correct perioral rhytides in adults over the age of 21.
An investigational topical prescription product for the treatment of persistent facial erythema associated with rosacea in adults has been accepted by the Food and Drug Administration (FDA) for standard review.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Bocouture, a botulinum neurotoxin type A treatment, in the UK for treatment of upper facial lines.
Results of a new study indicate that Botox (onabotulinumtoxinA, Allergan) can be used to treat crow’s feet lines safely and effectively.
A new study published in Dermatologic Surgery in April suggests platelet-rich plasma (PRP) has a positive effect on androgenetic alopecia (AGA).
The Food and Drug Administration (FDA) has approved the Taltz injection to treat adults with moderate-to-severe psoriasis.
Global pharmaceutical company Allergan has received approval from the FDA for a topical acne treatment.
Breast implant manufacturer Mentor has received Food and Drug Administration (FDA) and Investigational Device Exemption (IDE) approval to initiate a clinical trial studying larger breast implants.
Pharmaceutical manufacturer mesoestetic Pharma Group will launch a new acne line called acnelan at an international event in Barcelona on December 3 and 4.